Article
Comparison of Frequency and Sensitivity of BCR-ABL1 Kinase Domain Mutations in Asian and White Patients With Imatinib-resistant Chronic-Phase Chronic Myeloid Leukemia.
Clinical lymphoma, myeloma & leukemia - 1 Oct 2018
Kim Hawk, Kim SooHyun, Kim Hyeoung-Joon, Kim Yeo-Kyeoung, Kwak Jae-Yong, Yhim Ho-Young, Kim Sung-Hyun, Do Young Rok, Oh Sukjoong, Lee Sung-Eun, Jootar Saengsuree, Cui Jiu Wei, Kim Dong-Wook
Abstract excerpt
INTRODUCTION: BCR-ABL1 mutations require consideration during second-line tyrosine kinase inhibitor selection for patients with chronic myeloid leukemia (CML). The present retrospective analysis compared the frequency of BCR-ABL1 mutations in Asian and white patients in whom imatinib therapy had failed. PATIENTS AND METHODS: A nonstudy cohort (76 Asian patients from community clinical practices) and 2 study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.